Effect of Basis™ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance

Elysium Health

Status and phase

Withdrawn

Phase 1

Conditions

Healthy

Treatments

Dietary Supplement: Placebo oral capsule

Dietary Supplement: NRPT

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT04050358

Basis-HIIT

Details and patient eligibility

About

This is a single-center, randomized, placebo-controlled pilot study to evaluate the effects of high intensity interval training (HIIT) and daily administration of BasisTM for 3 weeks, in 18-35 year old males.

The study will consist of a screening visit, baseline visit, followed by treatment and HIIT phase (3 weeks) and a post-supplementation, follow-up visit (this will occur 48 h (or more) after the final HIIT session). Following the screening phase, subjects who meet entry criteria will be randomly assigned to 1 of 2 treatment groups: recommended dose of BasisTM (250 mg Nicotinamide Riboside and 50 mg Pterostilbene) per day or matching-placebo in a 1:1 ratio.

Sex

Male

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

18 to 35 year old males
Body mass index between 18.5-30 kg.m-2
Ability to give informed consent
Recreationally active (defined in the present study as exercising once a week or more).

Exclusion criteria

Those regularly conducting HIIT or highly trained in endurance events (e.g. triathlete)
Currently taking supplements known to affect metabolism (e.g. ibuprofen, stimulants, vitamins, NR)
Taking prescribed medication
Consuming a vegan diet
Consuming a high fat, low carbohydrate diet
Habitual consumption of protein and/or dairy supplements (e.g. whey protein)
Smokers